Anthony Hunt sold $4.1M of RGEN
director at REPLIGEN CORP. 26,756 shares at an average of $152.51, traded Mar 17, 2025, filed Mar 19, 2025.
Score components
- +15RoleDirector
- +25Trade size$4.1M at market
- +5Share of holdings soldSold 16% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-042026, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2025 | MOption exercise Common Stock10b5-1 | +5,000 | $33.87 | $169k | 141,301 | Mar 19, 2025 |
| Mar 17, 2025 | MOption exercise Common Stock10b5-1 | +21,756 | $59.52 | $1.3M | 163,057 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -60 | $148.05 | $8,883 | 162,997 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $150.38 | $15k | 162,897 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,518 | $151.09 | $380k | 160,379 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -6,176 | $151.96 | $939k | 154,203 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -15,619 | $152.82 | $2.4M | 138,584 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,283 | $153.70 | $351k | 136,301 | Mar 19, 2025 |
| Mar 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 202,344 | Mar 19, 2025 |
| Mar 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -21,756 | $0.00 | $0 | 0 | Mar 19, 2025 |
Related signals
Other insiders at REPLIGEN CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $1.0M 5,535 shares | -12% | |
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $2.5M 12,946 shares | -23% | |
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $977k 5,426 shares | -10% | |
| 23Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $504k 3,035 shares | -6% | |
| 21Weak | RGENsell REPLIGEN CORP | Karen A Dawes director | $44k 275 shares | -0% | |
| 50Moderate | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $1.2M 7,041 shares | -16% | |
| 50Moderate | REPLIGEN CORP | James Bylund Chief Operating Officer | $331k 2,191 shares | -9% | |
| 45Moderate | REPLIGEN CORP | Anthony Hunt director | $3.1M 20,000 shares | -20% | |
| 25Weak | REPLIGEN CORP | Anthony Hunt director | $3.9M 25,000 shares | -20% | |
| 30Weak | RGENsell REPLIGEN CORP | Anthony Hunt director | $3.5M 29,111 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.